GlassScriptPhysician profile
Steve Novak
NPI 1063542637
$524.83
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $168 · 2021: $54.44.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $133.84 | 2019 | |
| Glaxosmithkline, LLC. | $114.14 | 2020-2021 | |
| Lilly USA, LLC | $91.58 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $74.26 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $44.67 | 2019-2020 | |
| Novo Nordisk INC | $32.69 | 2020 | |
| Si-Bone, INC. | $21.40 | 2019 | |
| Abbvie INC. | $12.25 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Novak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.